|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
11 months to Dec 31, 2022
|
|
|---|---|---|---|---|
| Cash flows used in operating activities: | ||||
| Net loss | ||||
| Adjustments to reconcile net loss to net cash used in operating activities: | ||||
| Depreciation expense | ||||
| Equity-based compensation | ||||
| Amortization of debt discount | ||||
| Change in fair value of derivative liabilities | ||||
| Loss on extinguishment of debt | ||||
| Non-cash lease expense | ||||
| Issuance of shares to settle asset purchase agreement | ||||
| Interest receivable | ||||
| Prepaid expenses | ||||
| Deferred offering costs | ||||
| Other assets | ||||
| Accounts payable | ||||
| Accrued liabilities | ||||
| Net cash used in operating activities | ||||
| Cash flows used in investing activities: | ||||
| Investment in property and equipment | ||||
| Net cash used in investing activities | ||||
| Cash flows from financing activities: | ||||
| Proceeds from sale of common stock, pre-funded warrants and warrants in private placement, net of fees | ||||
| Issuance costs from warrant inducement | ||||
| Proceeds from sale of common stock under ATM | ||||
| Issuance costs for sale of common stock under ATM | ||||
| Proceeds from the sale of common stock and warrants | ||||
| Issuance costs for the sale of common stock and warrants | ||||
| Proceeds from exercise of warrants | ||||
| Repayment of promissory notes | ||||
| Proceeds from sale of common stock in initial public offering, net of offering costs | ||||
| Proceeds from exercise of stock options | ||||
| Net cash provided by financing activities | ||||
| Net change in cash and cash equivalents | ||||
| Cash and cash equivalents – beginning of the period | ||||
| Cash and cash equivalents – end of the period | ||||
| Issuance of common shares for consulting services | ||||
| Issuance of common shares to settle convertible debt | ||||
| De-recognition of derivative liabilities | ||||
Loading...